PortalPublikationenManagement of medication overuse (MO) and medication overuse...

Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline

Standard

Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. / Diener, Hans-Christoph; Kropp, Peter; Dresler, Thomas; Evers, Stefan; Förderreuther, Stefanie; Gaul, Charly; Holle-Lee, Dagny; May, Arne; Niederberger, Uwe; Moll, Sabrina; Schankin, Christoph; Lampl, Christian.

in: Neurol Res Pract, Jahrgang 4, Nr. 1, 37, 29.08.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Diener, H-C, Kropp, P, Dresler, T, Evers, S, Förderreuther, S, Gaul, C, Holle-Lee, D, May, A, Niederberger, U, Moll, S, Schankin, C & Lampl, C 2022, 'Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline', Neurol Res Pract, Jg. 4, Nr. 1, 37. https://doi.org/10.1186/s42466-022-00200-0

APA

Diener, H-C., Kropp, P., Dresler, T., Evers, S., Förderreuther, S., Gaul, C., Holle-Lee, D., May, A., Niederberger, U., Moll, S., Schankin, C., & Lampl, C. (2022). Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurol Res Pract, 4(1), [37]. https://doi.org/10.1186/s42466-022-00200-0

Vancouver

Diener H-C, Kropp P, Dresler T, Evers S, Förderreuther S, Gaul C et al. Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurol Res Pract. 2022 Aug 29;4(1). 37. https://doi.org/10.1186/s42466-022-00200-0

Bibtex

@article{58f073488191465b8755baba991f2c5e,
title = "Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline",
abstract = "INTRODUCTION: Chronic headache due to the overuse of medication for the treatment of migraine attacks has a prevalence of 0.5-2.0%. This guideline provides guidance for the management of medication overuse (MO) and medication overuse headache (MOH).RECOMMENDATIONS: Treatment of headache due to overuse of analgesics or specific migraine medications involves several stages. Patients with medication overuse (MO) or medication overuse headache (MOH) should be educated about the relationship between frequent use of symptomatic headache medication and the transition from episodic to chronic migraine (chronification), with the aim of reducing and limiting the use of acute medication. In a second step, migraine prophylaxis should be initiated in patients with migraine and overuse of analgesics or specific migraine drugs. Topiramate, onabotulinumtoxinA and the monoclonal antibodies against CGRP or the CGRP-receptor are effective in patients with chronic migraine and medication overuse. In patients with tension-type headache, prophylaxis is performed with amitriptyline. Drug prophylaxis should be supplemented by non-drug interventions. For patients in whom education and prophylactic medication are not effective, pausing acute medication is recommended. This treatment can be performed in an outpatient, day hospital or inpatient setting. Patients with headache due to overuse of opioids should undergo inpatient withdrawal. The success rate of the stepped treatment approach is 50-70% after 6 to 12 months. A high relapse rate is observed in patients with opioid overuse. Tricyclic antidepressants, neuroleptics (antiemetics) and the administration of steroids are recommended for the treatment of withdrawal symptoms or headaches during the medication pause. Consistent patient education and further close monitoring reduce the risk of relapse.",
author = "Hans-Christoph Diener and Peter Kropp and Thomas Dresler and Stefan Evers and Stefanie F{\"o}rderreuther and Charly Gaul and Dagny Holle-Lee and Arne May and Uwe Niederberger and Sabrina Moll and Christoph Schankin and Christian Lampl",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = aug,
day = "29",
doi = "10.1186/s42466-022-00200-0",
language = "English",
volume = "4",
journal = "Neurol Res Pract",
issn = "2524-3489",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline

AU - Diener, Hans-Christoph

AU - Kropp, Peter

AU - Dresler, Thomas

AU - Evers, Stefan

AU - Förderreuther, Stefanie

AU - Gaul, Charly

AU - Holle-Lee, Dagny

AU - May, Arne

AU - Niederberger, Uwe

AU - Moll, Sabrina

AU - Schankin, Christoph

AU - Lampl, Christian

N1 - © 2022. The Author(s).

PY - 2022/8/29

Y1 - 2022/8/29

N2 - INTRODUCTION: Chronic headache due to the overuse of medication for the treatment of migraine attacks has a prevalence of 0.5-2.0%. This guideline provides guidance for the management of medication overuse (MO) and medication overuse headache (MOH).RECOMMENDATIONS: Treatment of headache due to overuse of analgesics or specific migraine medications involves several stages. Patients with medication overuse (MO) or medication overuse headache (MOH) should be educated about the relationship between frequent use of symptomatic headache medication and the transition from episodic to chronic migraine (chronification), with the aim of reducing and limiting the use of acute medication. In a second step, migraine prophylaxis should be initiated in patients with migraine and overuse of analgesics or specific migraine drugs. Topiramate, onabotulinumtoxinA and the monoclonal antibodies against CGRP or the CGRP-receptor are effective in patients with chronic migraine and medication overuse. In patients with tension-type headache, prophylaxis is performed with amitriptyline. Drug prophylaxis should be supplemented by non-drug interventions. For patients in whom education and prophylactic medication are not effective, pausing acute medication is recommended. This treatment can be performed in an outpatient, day hospital or inpatient setting. Patients with headache due to overuse of opioids should undergo inpatient withdrawal. The success rate of the stepped treatment approach is 50-70% after 6 to 12 months. A high relapse rate is observed in patients with opioid overuse. Tricyclic antidepressants, neuroleptics (antiemetics) and the administration of steroids are recommended for the treatment of withdrawal symptoms or headaches during the medication pause. Consistent patient education and further close monitoring reduce the risk of relapse.

AB - INTRODUCTION: Chronic headache due to the overuse of medication for the treatment of migraine attacks has a prevalence of 0.5-2.0%. This guideline provides guidance for the management of medication overuse (MO) and medication overuse headache (MOH).RECOMMENDATIONS: Treatment of headache due to overuse of analgesics or specific migraine medications involves several stages. Patients with medication overuse (MO) or medication overuse headache (MOH) should be educated about the relationship between frequent use of symptomatic headache medication and the transition from episodic to chronic migraine (chronification), with the aim of reducing and limiting the use of acute medication. In a second step, migraine prophylaxis should be initiated in patients with migraine and overuse of analgesics or specific migraine drugs. Topiramate, onabotulinumtoxinA and the monoclonal antibodies against CGRP or the CGRP-receptor are effective in patients with chronic migraine and medication overuse. In patients with tension-type headache, prophylaxis is performed with amitriptyline. Drug prophylaxis should be supplemented by non-drug interventions. For patients in whom education and prophylactic medication are not effective, pausing acute medication is recommended. This treatment can be performed in an outpatient, day hospital or inpatient setting. Patients with headache due to overuse of opioids should undergo inpatient withdrawal. The success rate of the stepped treatment approach is 50-70% after 6 to 12 months. A high relapse rate is observed in patients with opioid overuse. Tricyclic antidepressants, neuroleptics (antiemetics) and the administration of steroids are recommended for the treatment of withdrawal symptoms or headaches during the medication pause. Consistent patient education and further close monitoring reduce the risk of relapse.

U2 - 10.1186/s42466-022-00200-0

DO - 10.1186/s42466-022-00200-0

M3 - SCORING: Journal article

C2 - 36031642

VL - 4

JO - Neurol Res Pract

JF - Neurol Res Pract

SN - 2524-3489

IS - 1

M1 - 37

ER -